ALNYLAM PHARMACEUTICALS, INC. Q3 FY2026 earnings call

• Commercial Execution: Amvuttra adoption is accelerating but not yet at the pace management desires; expanded sales force engagement has increased prescriber reach but translation to patient starts faces lag due to physician unfamiliarity with the disease and non-clinical barriers like prior authorization.
• Pipeline Expansion (Triton CM): Enrollment for Triton CM study expanded to ~2,250 patients (+500) to account for lower background event rates and ensure statistical power; launch timeline remains targeted for 2030.
• Huntington’s Disease Progress: Berzosaran showed robust dose-dependent mutant HTT reduction (60-64%) with favorable safety signals in Phase I; pivotal study planned for 2027 pending regulatory alignment.
• Access & Payer Dynamics: UnitedHealth implemented restrictive first-line policies for Medicare Advantage (impact limited to new patients); CMS 340B rule finalization expected imminently with Jan 1, 2027 effective date.

Total net product revenues reached approximately $1.3 billion, representing a 52% year-over-year increase. The TTR franchise contributed $1.15 billion (nearly 60% of total revenue), driven by Amvuttra uptake. Collaboration revenue was $71 million (80% decrease YoY due to the absence of Roche's one-time milestone), and royalty revenue was $95 million.

• Reiterated full-year 2026 TTR product sales guidance of $4.2–$4.5 billion, expecting to land at the low end.
• Withheld 2027 product revenue guidance until Q4/FY2026 results in mid-February to assess post-340B rule ordering behaviors.
• Anticipated headwinds in Q4 2026 from inventory normalization and potential U.S. pricing pressures.

• Regulatory/Reimbursement: Final CMS 340B rule could disrupt hospital procurement economics, potentially impacting gross-to-net adjustments and volume if health systems shift purchasing channels or sites of care.
• Payer Restrictions: More restrictive first-line access policies in Medicare Advantage may delay new patient starts.
• Clinical Trial Risks: Triton CM enrollment expansion required to mitigate risk of under-powering due to secular trends in lower cardiovascular event rates among treated ATTR-CM patients.

Q: Analyst asked about potential further changes to the Triton CM trial design beyond enrollment expansion, such as endpoint modifications.

A: Management clarified that the primary hypothesis and therapeutic expectations remain unchanged; the 500-patient increase solely addresses lower-than-expected background event rates to ensure adequate statistical power. They noted the study is event-driven, allowing for future analytic plan tweaks if warranted, but no immediate structural changes were made.

Q: Analyst questioned why expanded field force engagements have not yet translated into faster demand growth.

A: CEO Yvonne Greenstreet explained that while engagement is up, converting new physicians (who lack familiarity with ATTR-CM) into regular prescribers takes time due to entrenched habits and administrative hurdles. Tolga Tanguler added that non-clinical barriers like prior authorization are significant initially but ease once physicians experience the support infrastructure, emphasizing that 'experience begets preference.'

Q: Analyst sought clarity on the financial impact of the proposed 340B rule on net price and volume.

A: CFO Jeff Poulton stated it is premature to quantify impacts, but outlined scenarios: if hospitals stay in 340B, Alnylam may offer discounts to maintain viability, lowering net price; if they shift to WAC or alternate sites of care, net price could improve. Volume impact depends on whether physicians prioritize clinical efficacy over reimbursement complexities, which historically drives Amvuttra choice.

Q: Analyst asked about the timing and content of upcoming HHT and obesity data releases.

A: Pushkal Garg confirmed no delays in study progress; ALN2232 (obesity) and ALN6400 (HHT) data will report in Q4 earnings due to calendar timing. ALN2232 will show adipose targeting safety/knockdown and biometrics, while ALN6400 will provide proof-of-concept efficacy and safety data, continuing their pipeline momentum toward 2030 goals.